Arcturus Therapeutics Holdings Inc.

Biotechnology • Healthcare • San Diego, CA, United States • ARCT (NGM)

Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis. Its product pipeline includes KOSTAIVE for the treatment of covid 19; ARCT-2138 (LUNAR-FLU), which is in phase 1 clinical trial for the treatment of seasonal influenza; ARCT-2304 (LUNAR-H5N1) that is in phase 1 clinical trial for the treatment of Pandemic Influenza; ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3 clinical trial; and ARCT-2303 for monovalent that is in Phase 3 clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Stock Performance (90 Days)

Data through Dec 24, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Citigroup Maintains Arcturus Therapeutics Holdings (ARCT) Neutral Recommendation - Nasdaq

Nasdaq • Nov 13

Arcturus Therapeutics (ARCT) Surges 8.7%: Is This an Indication of Further Gains? - Yahoo Finance

Yahoo Finance • Sep 19

Arcturus' stock halves after mRNA therapy fails to evoke efficacy in cystic fibrosis trial - Fierce Biotech

Fierce Biotech • Oct 22

This Biotech, Up 188% Since April, Just Crashed 50%. Here's Why. - Investor's Business Daily

Investor's Business Daily • Oct 22

Arcturus Therapeutics Announces CFO Departure and Replacement - TipRanks

TipRanks • Dec 15

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has Arcturus Therapeutics Holdings Inc. had layoffs?

No layoff events have been recorded for Arcturus Therapeutics Holdings Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does Arcturus Therapeutics Holdings Inc. have?

Arcturus Therapeutics Holdings Inc. has approximately 174 employees.

What industry is Arcturus Therapeutics Holdings Inc. in?

Arcturus Therapeutics Holdings Inc. operates in the Biotechnology industry, within the Healthcare sector.

Is Arcturus Therapeutics Holdings Inc. a publicly traded company?

Yes, Arcturus Therapeutics Holdings Inc. is publicly traded under the ticker symbol ARCT on the NGM. The company has a market capitalization of approximately $0.18 billion.

Where is Arcturus Therapeutics Holdings Inc. headquartered?

Arcturus Therapeutics Holdings Inc. is headquartered in San Diego, CA, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.